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1. Introduction 
Activation of coagulation factor X by factor VIIa 
and tissue factor [1 ] presumably occurs in response 
to tissue damage. This was an important coagulation 
reaction to study with respect o plasma high density 
lipoprotein (HDL) because: 
(1) Tissue factor is a membrane protein dependent 
on association with a phospholipid bilayer for its 
cofactor activity [2-4]; 
(2) HDL is capable of destabilizing phospholipid 
vesicles [5-8] and could therefore influence the 
initiation of coagulation by tissue factor; 
(3) HDL is statistically elevated in populations with 
low incidence of atherosclerosis [9-14]. 
Investigations oflipoprotein effects on the intrinsic 
(contact) pathway of coagulation, and on activation 
of prothrombin, have shown that lipoproteins can 
serve as the phospholipid required in these reactions 
[ 15-17]. Thcse studies, however, dealt with the final 
reactions of the pathway rather than the early reac- 
tions, or did not isolate the primary reactions from 
later lipid-dependent reactions. This report describes 
the inhibitory effect of HDL on the extrinsic pathway 
of coagulation using the isolated reaction, tissue factor- 
dependent activation of factor X. 
2. Materials and methods 
Lipoproteins from fasted donors were separated 
from plasma by ultracentrifugation [18] using KBr 
steps of 1.26 g/ml, 1.21 g/ml and 1.06 g/ml, overlayed 
with a step of 0.15 M NaC1. The 1.06 g/ml fraction 
and 1.21 g/ml fraction (HDL) were collected, made 
to 1.26 g/ml with KBr, and reisolated by a second 
centrifugation. The isolated lipoproteins were dia- 
lyzed against 0.05 M Tris, 0.1 M NaC1, 0.01% NaN3 
(pH 7.6) (Tris-saline buffer). The HDL and 1.06 g/ml 
fractions were examined by immunoelectrophoresis 
[19] and by polyacrylamide g l electrophoresis in 
sodium dodecyl sulfate (SDS) [20]. The lipid and 
protein components of HDL were separated by 
extraction twice with an equal volume of chloroform- 
methanol (2:1) [21 ]. The solvents were evaporated 
from the lipids under N2. The apoproteins were dia- 
lyzed against Tris-saline buffer and stored at -20°C. 
The lipids were resuspended in Tris-saline buffer and 
sonicated under N2 in a bath sonicator (Branson) just 
prior to use. 
Human tissue factor was purified 2000-fold from 
placenta nd reconstituted with bovine brain lipids by 
dialysis [3]. Bovine brain tissue factor was a homoge- 
neous preparation kindly provided by Dr Ron Bach 
[22,23]. The bovine tissue factor was reconstituted 
with bovine brain lipids; CdC12 and deoxycholate were 
removed by gel filtration of the reconstituted mixture 
(1 ml containing 1.14 ng tissue factor, 0.5 mg mixed 
brain lipids in deoxycholate, 5 mM CdC12 and bovine 
serum albumin at I mg/ml [3,4]) on a column of 
Bio-Gel A5m (13.5 X 1.5 cm). Tissue factor coagulant 
activity was measured in a 2-stage assay [24] in which 
purified bovine factors X and VIIa (provided by 
Dr Yale Nemerson) were used in the first stage at 
19.8 and 0.5 nM, respectively. 
The radiometric assay in [25] was used to measure 
the activation of factor X by factor VIIa and tissue 
factor. The assay concentrations of tritiated factor X 
(148 000 cpm//Jg) and factor VIIa were 422 nM and 
1.49 nM, respectively. The effects of lipoproteins on 
tissue factor activity were assessed by incubating the 
lipoproteins with relipidated tissue factor at 37°C in 
160 #1. The remaining reagents were added after 
15 min and gave a final reaction volume of 200 pl. 
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Lipoprotein effects on tissue factor coagulant 
activity were assessed by combining relipidated tissue 
factor and purified l ipoprotein, (final vol. 100 gl) in 
microtiter wells. The mixture was incubated at 37°C. 
After 15 min, 20/A of the tissue factor l ipoprotein 
mixture were combined with factor X, VIIa, and 
Ca 2+ in the first stage of the coagulation assay (first 
stage volume was 60/11). 
Protein concentrations were determined by amino 
acid analysis on a Beckman 121M analyzer after 24 h 
acid hydrolysis. Phospholipid concentrations were 
determined according to [26]. 
3. Results 
The experiments with human placental tissue factor 
showed that HDL inhibited tissue factor coagulant activ- 
ity (fig.l). The ability of the protein constituents of 
HDL (apoHDL) to withstand organic extraction of the 
HDL lipids permitted separate valuation of apoHDL 
and HDL lipids. Chloroform-methanol  extraction 
reduced the lipid/protein ratio from ~1 nmol PO4//Jg 
HDL protein in the intact l ipoprotein, to <0.1 nmol 
PO4///g protein in the apoHDL preparations. The 
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F]g.l. Effects of HDL (open symbols) and apoHDL (closed 
symbols) on human placental tissue factor. Lipoprotein con- 
centrations are those used in the 0.1 ml incubation with tissue 
factor. Donors were G.G. (o,.) and S.D.C.1 (D). One apoHDL 
was from HDL kindly provided by Dr Janet Boyles from an 
anonymous donor (A). The phospholipid content of the prep- 
arations (nmol POJug protein) were: 1.0 (o); 0.7 (~); <0.02 
(*); 0.09 (A). 
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Fig.2. Effects of HDL on bovine brain tissue factor coagulant 
activity. Lipoproteins were prepared from donors S.D.C.2 (*), 
J.S. (A) and S.M.C. (.). 
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ac t ivat ion  by  t i ssue fac tor  and  fac tor  V I Ia .  The  p lasma donor  
was  S .D.C .  L ipoprote in  concent ra t ions  are those  in the  com-  
p lete  react ion  mix ture  (200  ul) .  
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Table 1 
ApoHDL and HDL lipid effects on bovine brain tissue factor coagulant activity 
(tissue factor alone: 20.7 +- 2.0 units/ml) 
Donor: S.D.C. 2 Donor: S.M.C. 
apoHDL a Lipid a Tissue factor, apoHDL Lipid Tissue factor 
(ug) (nmol PO4) (units/ml) (tsg) (nmol PO,) (units/ml) 
2.0 13,0 2.0 15.5 
5.0 < 1.6 13,5 5.0 0 13.0 
10.0 8.8 10.0 12.5 
4.0 20.0 
8.0 22.0 
20.0 24.0 
40.0 23.5 
a Quantities are as used in tile 0.1 ml incubation with tissue factor; concentra- 
tions (~g/ml) used in the first stage of the assay are derived by multiplying by 
3.33 
b This chloroform-methanol extract of HDL inhibited tissue factor activity, but 
the electrophoretic analysis revealed aprominent apoA4 protein. All other HDL 
lipid preparations contained no detectable protein component 
apoHDL, as for the intact l ipoprotein, inhibited tissue 
factor activity (r iga).  In the presence of the extracted 
lipids (tested at 46-260 nmol PO4/ml), however, full 
tissue factor activity was retained (42,6-52.0 units/ml). 
The results obtained with human placental tissue 
factor were confirmed using a homogeneous prepara- 
tion of bovine brain tissue factor. HDL from 3 donors 
inhibited tissue factor coagulant activity (fig.2). 
ApoHDLinhibited bovine tissue factor coagulant activ- 
ity (table 1) while the lipid component was not inhib- 
itory. Conclusive vidence that the inhibition of coag- 
ulant activity was due to lipoprotein effects on the 
activation of factor X by tissue factor and factor Vl la 
was obtained using the direct radiometric assay of 
factor X activation. HDL produced a striking decrease 
in the velocity of factor X activation (fig.3). 
The 1.06 g/ml preparations also inhibited tissue 
factor coagulant activity. Although these preparations 
had each produced a single immunoprecipitate similar 
to LDL, small amounts of protein other than apoB 
were detected after electrophoresis in the presence of 
SDS. This indicated that the 1.06 g/ml fraction prob- 
ably contained some VLDL or IDL in addition to 
LDL. Studies with the 1.06 g/ml preparations were 
not pursued further. 
4. Discussion 
Based on 1.2 mg apoA-I/ml, the major protein 
component of HDL [27-29] ,  HDL at 8.3% of plasma 
concentration i hibited coagulant activity of both 
human and bovine tissue factor by ~25%. In the 
radiometric assay, the same concentration of HDL 
inhibited factor X activation by 54%. In the coagula- 
tion assay, factors X and VII are used at 25% and 6.5% 
of their respective human plasma concentrations. They 
are used at 520% (factor X) and 20% (factor VII) of 
their plasma concentrations in the radiometric assay 
[30,31 ]. Therefore, in all of the experiments, inhibi- 
tion of factor X activation was observed when the 
concentrations of HDL relative to factors X and VII 
were near or below their respective l vels in human 
plasma. 
Although phospholipid constitutes 25% or more of 
the weight of holoHDL [32], extracted lipids had no 
inhibitory effect on tissue factor coagulant activity. 
On the other hand, apoHDL was as inhibitory as 
holoHDL. These results uggest that inhibition of 
tissue factor activity is due to a specific interaction 
between the lipoprotein and tissue factor. The princi- 
pal protein of HDL, apo-A-I, is capable of exchanging 
from HDL to phospholipid vesicles [5-8] .  ApoA-II, 
apoC, and apoE are also reversibly associated with 
plasma lipoproteins [33]. Exchange of apolipopro- 
teins from lipoproteins to vesicles containing tissue 
factor could alter the tissue factor coagulant activity 
by direct effect on tissue factor, by restricting the 
access of enzyme and substrate to the cofactor -  
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vesicle surface, or by altering some essential structural 
feature of the vesicle. The presence of tissue factor in 
arterial endothelium and atherosclerotic plaques [34], 
the ability of lipoproteins to inhibit tissue factor- 
dependent activation of factor X while promoting the 
factor Xa conversion of prothrombin to thrombin 
[15-17],  and the relationship between plasma lipo- 
proteins and cardiovascular disease [9-141 suggest 
that understanding tissue factor expression and regula- 
tion may be relevant to studies of atherosclerosis. 
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